EMA Withdrawn: Nodetrip (previously Xeristar) (duloxetine) — Esteve Pharmaceuticals, S.A.

View source ↗

Summary

The EMA has withdrawn Nodetrip (duloxetine) from Esteve Pharmaceuticals, covering indications in anxiety disorders, major depressive disorder, and diabetic neur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Diabetic Neuropathy
• Major Depressive Disorder

Drugs mentioned

• Nodetrip (duloxetine)

Snippet

Status: Withdrawn. Therapeutic area: Anxiety Disorders;Depressive Disorder, Major;Diabetic Neuropathies. MAH: Esteve Pharmaceuticals, S.A.. Decision date: 12/05/2021